

UNITED KINGDOM

Animal health/Official certificate to the EU

Part I: Description of consignment	I.1 Consignor/Exporter		I.2 Certificate reference		I.2a	
	Name					
	Address		I.3 Central Competent Authority DEPARTMENT FOR ENVIRONMENT, FOOD & RURAL AFFAIRS			
	Country		ISO country code		I.4 Local Competent Authority ANIMAL AND PLANT HEALTH AGENCY	
	I.5 Consignee/Importer			I.6 Operator responsible for the consignment		
	Name			Name		
	Address			Address		
	Country			ISO country code		
	Country			ISO country code		
	I.7 Country of origin			I.9 Country of destination		
	ISO country code			ISO country code		
	I.8 Region of origin			I.10 Region of destination		
	Code			Code		
	I.11 Place of dispatch			I.12 Place of destination		
	Registration/Approval No			Registration/Approval No		
Name			Name			
Address			Address			
Country			ISO country code			
Country			ISO country code			
I.13 Place of loading			I.14 Date and time of departure			
I.15 Means of transport			I.16 Entry Border Control Post			
☐ Aircraft ☐ Vessel			I.17 Accompanying documents			
☐ Railway ☐ Road vehicle			Type ☐ Code			
Identification			Country			
			ISO country code			
			Commercial document reference			
I.18 Transport conditions						
☐ Ambient ☐ Chilled ☐ Frozen						
I.19 Container number/Seal number						
Container No			Seal No			
I.20 Certified as or for						
☐ Germinal products						
I.21			I.22			
☐ For transit			☐ For internal market			
Third country			ISO country code			
I.24 Total number of packages			I.25 Total quantity		I.26	

I.27 Description of consignment

1

CN code	Species	Subspecies/Category	Identification number	Quantity
---------	---------	---------------------	-----------------------	----------

Type	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
------	---	---------------------	-------------------------------	------

2

CN code	Species	Subspecies/Category	Identification number	Quantity
---------	---------	---------------------	-----------------------	----------

Type	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
------	---	---------------------	-------------------------------	------

3

CN code	Species	Subspecies/Category	Identification number	Quantity
---------	---------	---------------------	-----------------------	----------

Type	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
------	---	---------------------	-------------------------------	------

4

CN code	Species	Subspecies/Category	Identification number	Quantity
---------	---------	---------------------	-----------------------	----------

Type	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
------	---	---------------------	-------------------------------	------

5

CN code	Species	Subspecies/Category	Identification number	Quantity
---------	---------	---------------------	-----------------------	----------

Type	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
------	---	---------------------	-------------------------------	------

UNITED KINGDOM

II. Health information

I, the undersigned official veterinarian, hereby certify that:

- II.1. The [oocytes] ⁽¹⁾ [in vivo derived embryos] ⁽¹⁾ [in vitro produced embryos] ⁽¹⁾ [micromanipulated embryos] ⁽¹⁾ described in Part I are intended for artificial reproduction and were obtained from donor animals which originate:
- II.1.1. from a third country or territory, or zone thereof:
- II.1.1.1. authorised for the entry into the Union of [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ of equine animals and listed in Annex XII to Commission Implementing Regulation (EU) 2021/404;
- II.1.1.2. free from African horse sickness for at least 24 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch in accordance with Article 22(2), point (a), of Commission Delegated Regulation (EU) 2020/692, and where no systematic vaccination against African horse sickness has been carried out for at least 12 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch in accordance with Article 22(4), point (b), of that Delegated Regulation;
- II.1.1.3. where Venezuelan equine encephalomyelitis was not reported for at least 24 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch;
- II.1.2. from an establishment in a third country or territory, or zone thereof:
- ⁽¹⁾ either [II.1.2.1. where infection with *Burkholderia mallei* (glanders) was not reported for at least 36 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch;]
- ⁽¹⁾ or [II.1.2.1. where infection with *Burkholderia mallei* (glanders) was not reported for at least 6 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch, and the Commission has recognised the surveillance programme carried out in breeding equine animals in the establishment of origin to demonstrate absence of infection during that period;]
- ⁽¹⁾ either [II.1.2.2. where dourine was not reported for at least 24 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch;]
- ⁽¹⁾ or [II.1.2.2. where dourine was not reported for at least 6 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch, and the Commission has recognised the surveillance programme carried out in breeding equine animals in the establishment of origin to demonstrate absence of infection during that period;]
- ⁽¹⁾ either [II.1.2.3. where surra (*Trypanosoma evansi*) was not reported for at least 24 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch;]
- ⁽¹⁾ or [II.1.2.3. where surra (*Trypanosoma evansi*) was not reported for at least 6 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and until the date of their dispatch, and the Commission has recognised the surveillance programme carried out in breeding equine animals in the establishment of origin to demonstrate absence of infection during that period.]]
- II.2. The [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ described in Part I were obtained from donor animals which originate from establishments:
- II.2.1. in which
- ⁽¹⁾ either [surra has not been reported during 2 years immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾.]
- ⁽¹⁾ or [surra has not been reported during the period of the preceding 30 days prior to [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾, and when the disease was reported in the establishments during the preceding 2 years prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ following the last outbreak, the establishments have remained under movement restrictions
- ⁽¹⁾ either [until the date on which the remaining animals in the establishments have been subjected to a test for surra with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the date on which the last infected animal has been removed from the establishments;]]
- ⁽¹⁾ or [for at least 30 days from the date of cleaning and disinfection and after the date on which the last animal of listed species in the establishments was either killed and destroyed or slaughtered.]]
- II.2.2. in which
- ⁽¹⁾ either [dourine has not been reported during the preceding 2 years prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾.]
- ⁽¹⁾ or [dourine has not been reported during the preceding 6 months prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾, and when the disease was reported in the establishments during the preceding 2 years prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ following the last outbreak, the establishments have remained under movement restrictions
- ⁽¹⁾ either [until the date on which the remaining equine animals in the establishments, except castrated male equine animals, have been subjected to a test for dourine with the diagnostic method provided for in Part 8 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the date on which the infected animals have been killed and destroyed or slaughtered, or the infected entire male equine animals have been castrated;]]

UNITED KINGDOM

	⁽¹⁾ or [for at least 30 days after the date on which the last equine animal in the establishments was either killed and destroyed or slaughtered, and the premises were cleaned and disinfected;]] II.2.3. in which ⁽¹⁾ either [equine infectious anaemia has not been reported during the preceding 12 months prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾]; ⁽¹⁾ or [equine infectious anaemia has not been reported during the preceding 90 days prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾, and when the disease was reported in the establishments during the preceding 12 months prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ following the last outbreak, the establishments have remained under movement restrictions ⁽¹⁾ either [until the date on which the remaining equine animals in the establishments have been subjected to a test for equine infectious anaemia with the diagnostic method provided for in Part 9 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken on two occasions with a minimum interval of 3 months after the date on which the infected animals have been killed and destroyed or slaughtered, and the establishments were cleaned and disinfected.]] ⁽¹⁾ or [for at least 30 days after the date on which the last equine animal in the establishments was either killed and destroyed or slaughtered, and the establishments were cleaned and disinfected.]] ⁽¹⁾ II.3. The [oocytes] ⁽¹⁾ [in vivo derived embryos] ⁽¹⁾ described in Part I have been collected, processed and stored, and dispatched by the embryo collection team ⁽²⁾ which: II.3.1. is approved and listed by the competent authority of the third country or territory; II.3.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.] ⁽¹⁾ II.3. The [oocytes] ⁽¹⁾ [in vitro produced embryos] ⁽¹⁾ [micromanipulated embryos] ⁽¹⁾ described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team ⁽²⁾ which: II.3.1. is approved and listed by the competent authority of the third country or territory; II.3.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.] II.4. The [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ described in Part I were obtained from donor animals which: II.4.1. were not vaccinated against African horse sickness at least in the last 40 days immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾; II.4.2. were not vaccinated against Venezuelan equine encephalomyelitis at least in the last 60 days immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾; II.4.3. remained for at least 3 months immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ in a third country or territory, or zone thereof referred to in box I.7; II.4.4. for at least 30 days immediately prior to the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and during the collection period: II.4.4.1. were kept in establishments not situated in a restricted zone established due to the occurrence of African horse sickness, infection with <i>Burkholderia mallei</i> (glanders) or of an emerging disease relevant for equine animals; II.4.4.2. were kept in establishments where Venezuelan equine encephalomyelitis, dourine, surra (<i>Trypanosoma evansi</i>), equine infectious anaemia, contagious equine metritis (<i>Taylorella equigenitalis</i>), infection with rabies virus and anthrax have not been reported; II.4.4.3. were not in contact with animals from establishments situated in a restricted zone due to the occurrence of diseases referred to in point II.4.4.1 or from establishments which do not meet the conditions referred to in point II.4.4.2; II.4.5. were not used for natural breeding during at least 30 days immediately prior to the date of the collection of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ and between the date on which the first samples referred to in points II.4.8.1 and II.4.8.2 were taken and the date of collection of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾; II.4.6. were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the date of [collection] ⁽¹⁾ [production] ⁽¹⁾ of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾; II.4.7. are individually identified as provided for in Article 21(2) of Delegated Regulation (EU) 2020/692; II.4.8. were subjected to the following tests, referred to in Part 4, Chapter II, points 2(b) and (c), of Annex II to Delegated Regulation (EU) 2020/686, as follows: ⁽³⁾ II.4.8.1. for equine infectious anaemia (EIA), an agar-gel immuno-diffusion test (AGID or Coggins test) or an enzyme-linked immunosorbent assay (ELISA) with a negative result carried out on a blood sample taken on _____ ⁽⁴⁾, being not less than 14 days following the date of commencement of the period referred to in point II.4.5 and not more than 90 days prior to the date of collection of the [oocytes] ⁽¹⁾ [embryos] ⁽¹⁾ intended for entry into the Union;] II.4.8.2. for contagious equine metritis (CEM), an agent identification test carried out with a negative result on at least two specimens (swabs) taken during the period referred to in point II.4.5 from at least the mucosal surfaces of the clitoral fossa and the clitoral sinuses of the donor mare: ⁽¹⁾ either II.4.8.2.1. on two occasions with an interval of not less than 7 days on _____ ⁽⁴⁾ and on _____ ⁽⁴⁾, in the case of isolation of <i>Taylorella equigenitalis</i> after cultivation under microaerophilic conditions for at least 7
--	--

UNITED KINGDOM

- days, set up within 24 hours after taking the specimens from the donor animal, or 48 hours where the specimens are kept cool during transport.]
- ⁽¹⁾ and/or [II.4.8.2.2. on one occasion on _____⁽⁴⁾, in the case of detection of the genome of *Taylorella equigenitalis* by a polymerase chain reaction (PCR) or real-time PCR, carried out within 48 hours immediately after taking the specimens from the donor animal.]
- The samples referred to in points II.4.8.2.1 and II.4.8.2.2 were in no case taken earlier than 7 days (systemic treatment) or 21 days (local treatment) after antimicrobial treatment of the donor mare and were placed in a transport medium with activated charcoal, such as Amies medium, before dispatch to the laboratory.
- II.5. The [oocytes]⁽¹⁾ [embryos]⁽¹⁾ described in Part I:
- II.5.1. have been collected, processed and stored in accordance with animal health requirements set out in [Part 2]⁽¹⁾ [Part 3]⁽¹⁾ [Part 4]⁽¹⁾ [Part 5]⁽¹⁾ and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;
- II.5.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 83, point (a), of Delegated Regulation (EU) 2020/692 and that mark is indicated in box I.27;
- II.5.3. are transported in a container which:
- II.5.3.1. was sealed and numbered prior to the dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in box I.19;
- II.5.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;
- ⁽¹⁾⁽⁵⁾ [II.5.3.3. has been filled in with a cryogenic agent which has not been previously used for other products.]
- ⁽¹⁾⁽⁶⁾ [II.5.4. are placed in straws or other packages which are securely and hermetically sealed;
- II.5.5. are transported in a container where the different types are separated from each other by physical compartments or by being placed in secondary protective bags.]
- ⁽¹⁾⁽⁷⁾ [II.6. The [*in vivo* derived embryos]⁽¹⁾ [*in vitro* produced embryos]⁽¹⁾ [micromanipulated embryos]⁽¹⁾ described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing or storage of semen by the competent authority of a third country or territory, or zone thereof listed in Annex XII to Implementing Regulation (EU) 2021/404 for semen of equine animals or by the competent authority of a Member State⁽⁸⁾, and were collected, processed and stored in accordance with the requirements of Part 4, Chapter I and Part 1 of Annex III to Delegated Regulation (EU) 2020/686.]
- ⁽¹⁾⁽⁹⁾ [II.7. The following antibiotic or mixture of antibiotics⁽¹⁰⁾ has been added to the collection, processing, washing or storage media: _____.]

Notes

This animal health certificate is intended for the entry into the Union of oocytes and embryos of equine animals, including when the Union is not the final destination of the oocytes and embryos.

In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Windsor Framework (see Joint Declaration No 1/2023 of the Union and the United Kingdom in the Joint Committee established by the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community of 24 March 2023, OJ L 102, 17.4.2023, p. 87) in conjunction with Annex 2 to that Framework, references to the Union in this animal health certificate include the United Kingdom in respect of Northern Ireland.

This animal health certificate shall be completed in accordance with the notes for the completion of certificates provided for in Chapter 4 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

- Box reference I.11: "Place of dispatch": Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos. Only embryo collection or production teams listed in accordance with Article 233(3) of Regulation (EU) 2016/429 on the Commission website: https://ec.europa.eu/food/animals/semen/equine_en.
- Box reference I.12: "Place of destination": Indicate the address and unique registration or approval number of the establishment of destination of the consignment of oocytes or embryos.
- Box reference I.19: Seal number shall be indicated.
- Box reference I.24: Total number of packages shall correspond to the number of containers.
- Box reference I.27: "Type": Specify if *in vivo* derived embryos, *in vivo* derived oocytes, *in vitro* produced embryos or micromanipulated embryos.
- "Identification number": Indicate the identification number of each donor animal.
- "Identification mark": Indicate the mark on the straw or other packages where oocytes or embryos of the consignment are placed.
- "Date of collection/production": Indicate the date on which oocytes or embryos of the consignment were collected or produced.
- "Approval or registration number of plant/establishment/centre": Indicate the unique approval number of the embryo collection or production team by which the oocytes or embryos of the consignment were collected or produced.
- "Quantity": Indicate the number of straws or other packages with the same mark.

UNITED KINGDOM

Part II:

- (1) Delete if not applicable.
- (2) Only embryo collection or production teams listed in accordance with Article 233(3) of Regulation (EU) 2016/429 on the Commission website: https://ec.europa.eu/food/animals/semen/equine_en.
- (3) The agar gel immunodiffusion test (AGID or Coggins test) or the ELISA for equine infectious anaemia are not required for donor equine animals which continuously resided in Iceland since birth, provided that Iceland remained officially free of equine infectious anaemia and no equine animals and their semen, ova and embryos were introduced into Iceland from outside prior to and during the period the ova or embryos were collected and the semen was used for fertilisation.
- (4) Insert date in the following format: dd.mm.yyyy.
- (5) Applicable for frozen oocytes or embryos.
- (6) Applicable for consignments where oocytes, *in vivo* derived embryos, *in vitro* produced embryos and micromanipulated embryos of equine animals are placed and transported in one container.
- (7) Does not apply to oocytes.
- (8) Only a semen collection centre, germinal product processing establishment or germinal product storage centre listed on the Commission websites for:
- (a) third countries or territories, or zones thereof: https://ec.europa.eu/food/animals/live_animals/approved-establishments_en;
- (b) Member States: https://ec.europa.eu/food/animals/semen/equine_en.
- (9) Mandatory attestation in case antibiotic(s) were added.
- (10) Insert the name(s) of the antibiotic(s) added and its (their) concentration.

Official veterinarian

Name (in capital letters)

Date

Qualification and title

Stamp

Signature